CGAS and metabolic dysfunction-associated steatotic liver disease: In addition to HBV and liver cancer, the cGAS–STING pathway has been shown to be activated in other kinds of liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD), alcohol liver disease (ALD), liver ischemia–reperfusion, etc.).